John Kao Sells 298,000 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 298,000 shares of Alignment Healthcare stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $20.36, for a total value of $6,067,280.00. Following the completion of the transaction, the chief executive officer owned 1,386,766 shares of the company’s stock, valued at approximately $28,234,555.76. This trade represents a 17.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alignment Healthcare Price Performance

Shares of Alignment Healthcare stock opened at $19.75 on Monday. The stock has a market cap of $4.08 billion, a price-to-earnings ratio of 219.44, a price-to-earnings-growth ratio of 2.67 and a beta of 1.14. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58. The stock has a 50 day moving average price of $18.53 and a 200-day moving average price of $19.41. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last announced its earnings results on Thursday, April 30th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.22 billion. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The company’s quarterly revenue was up 33.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.05) EPS. Equities analysts expect that Alignment Healthcare, Inc. will post 0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALHC. Wall Street Zen upgraded Alignment Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Barclays decreased their price target on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. Zacks Research raised Alignment Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 28th. KeyCorp reissued an “overweight” rating on shares of Alignment Healthcare in a research note on Wednesday. Finally, Weiss Ratings raised Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average price target of $24.30.

Institutional Investors Weigh In On Alignment Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the company. Summit Securities Group LLC bought a new stake in Alignment Healthcare during the 4th quarter valued at $26,000. Parallel Advisors LLC raised its position in Alignment Healthcare by 87.7% during the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after purchasing an additional 773 shares in the last quarter. Larson Financial Group LLC bought a new stake in Alignment Healthcare during the 3rd quarter valued at $33,000. First Horizon Corp bought a new stake in Alignment Healthcare during the 4th quarter valued at $39,000. Finally, GAMMA Investing LLC raised its position in Alignment Healthcare by 83.8% during the 4th quarter. GAMMA Investing LLC now owns 2,165 shares of the company’s stock valued at $43,000 after purchasing an additional 987 shares in the last quarter. 86.19% of the stock is owned by institutional investors.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.